Xvivo Perfusion AB/Skr XVIVO
08:00
10:05
12:15
14:20
16:25
1D1W1MYTD1Y5YMAX
About Xvivo Perfusion AB
Xvivo Perfusion AB is a biotechnology company specializing in the development and commercialization of medical devices and systems for organ transplantation. The company's core products include machine perfusion devices and solutions designed to preserve, evaluate, and transport donor organs, with a particular focus on lungs and hearts. Founded in 1998, Xvivo is headquartered in Gothenburg, Sweden, and has established a presence in key markets worldwide. The company's strategic positioning is enhanced by its commitment to improving transplantation outcomes through innovative technologies and research collaborations. Xvivo's expertise in organ preservation and perfusion technology provides competitive strengths in the field of regenerative medicine.
Ticker
Skr XVIVO
Sector
Primary listing
XSTO
Employees
198
Headquarters
Mölndal, Sweden
Website
XVIVO Metrics
BasicAdvanced
kr 6.8B
269.39
kr 0.80
1.86
-
Price and volume
Market cap
kr 6.8B
Beta
1.86
52-week high
kr 486.00
52-week low
kr 160.00
Average daily volume
202K
Financial strength
Current ratio
5.765
Quick ratio
3.684
Long term debt to equity
5.354
Total debt to equity
5.901
Interest coverage (TTM)
1.77%
Profitability
EBITDA (TTM)
138.485
Gross margin (TTM)
73.81%
Net profit margin (TTM)
3.10%
Operating margin (TTM)
10.88%
Effective tax rate (TTM)
34.74%
Revenue per employee (TTM)
kr 4,100,000
Management effectiveness
Return on assets (TTM)
2.31%
Return on equity (TTM)
1.18%
Valuation
Price to earnings (TTM)
269.391
Price to revenue (TTM)
8.346
Price to book
3.21
Price to tangible book (TTM)
4.64
Price to free cash flow (TTM)
67.072
Free cash flow yield (TTM)
1.49%
Free cash flow per share (TTM)
3.208
Growth
Revenue change (TTM)
-1.25%
Earnings per share change (TTM)
-85.32%
3-year revenue growth (CAGR)
25.05%
10-year revenue growth (CAGR)
21.05%
3-year earnings per share growth (CAGR)
8.81%
10-year earnings per share growth (CAGR)
12.85%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xvivo Perfusion AB stock?
Xvivo Perfusion AB (XVIVO) has a market cap of Skr6.8B as of February 03, 2026.
What is the P/E ratio for Xvivo Perfusion AB stock?
The price to earnings (P/E) ratio for Xvivo Perfusion AB (XVIVO) stock is 269.39 as of February 03, 2026.
Does Xvivo Perfusion AB stock pay dividends?
No, Xvivo Perfusion AB (XVIVO) stock does not pay dividends to its shareholders as of February 03, 2026.
When is the next Xvivo Perfusion AB dividend payment date?
Xvivo Perfusion AB (XVIVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xvivo Perfusion AB?
Xvivo Perfusion AB (XVIVO) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.